10X Net Income From Continuing Ops from 2010 to 2026
| TXG Stock | USD 18.61 0.91 5.14% |
Net Loss | First Reported 2018-09-30 | Previous Quarter 34.5 M | Current Value -27.5 M | Quarterly Volatility 75.5 M |
Check 10X Genomics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among 10X Genomics' main balance sheet or income statement drivers, such as Tax Provision of 3.9 M, Net Interest Income of 22.3 M or Interest Income of 22.3 M, as well as many indicators such as Price To Sales Ratio of 3.09, Dividend Yield of 0.0 or PTB Ratio of 2.08. 10X financial statements analysis is a perfect complement when working with 10X Genomics Valuation or Volatility modules.
10X | Net Income From Continuing Ops | Build AI portfolio with 10X Stock |
The Net Income From Continuing Ops trend for 10X Genomics offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether 10X Genomics is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest 10X Genomics' Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of 10X Genomics over the last few years. It is 10X Genomics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in 10X Genomics' overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
10X Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (107,968,166) | |
| Coefficient Of Variation | (126.61) | |
| Mean Deviation | 98,836,665 | |
| Median | (31,251,000) | |
| Standard Deviation | 136,703,558 | |
| Sample Variance | 18687.9T | |
| Range | 524M | |
| R-Value | (0.56) | |
| Mean Square Error | 13688.2T | |
| R-Squared | 0.31 | |
| Significance | 0.02 | |
| Slope | (15,152,983) | |
| Total Sum of Squares | 299005.8T |
10X Net Income From Continuing Ops History
About 10X Genomics Financial Statements
10X Genomics stakeholders use historical fundamental indicators, such as 10X Genomics' Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although 10X Genomics investors may analyze each financial statement separately, they are all interrelated. For example, changes in 10X Genomics' assets and liabilities are reflected in the revenues and expenses on 10X Genomics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in 10X Genomics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Loss | -164.4 M | -172.6 M |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out the analysis of 10X Genomics Correlation against competitors. For more detail on how to invest in 10X Stock please use our How to Invest in 10X Genomics guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Can Life Sciences Tools & Services industry sustain growth momentum? Does 10X have expansion opportunities? Factors like these will boost the valuation of 10X Genomics. If investors know 10X will grow in the future, the company's valuation will be higher. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating 10X Genomics demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share (0.58) | Revenue Per Share | Quarterly Revenue Growth (0.02) | Return On Assets | Return On Equity |
The market value of 10X Genomics is measured differently than its book value, which is the value of 10X that is recorded on the company's balance sheet. Investors also form their own opinion of 10X Genomics' value that differs from its market value or its book value, called intrinsic value, which is 10X Genomics' true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because 10X Genomics' market value can be influenced by many factors that don't directly affect 10X Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between 10X Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if 10X Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, 10X Genomics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.